- Home
- SSRM vs ORKA Comparison
SSRM vs ORKA Comparison
Compare SSRM & ORKA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | SSRM | ORKA |
|---|---|---|
| Founded | 1946 | 2004 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Precious Metals | Biotechnology: In Vitro & In Vivo Diagnostic Substances |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.5B | 1.5B |
| IPO Year | 1996 | N/A |
Fundamental Metrics
Financial Performance| Metric | SSRM | ORKA |
|---|---|---|
| Price | $23.10 | $31.62 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 5 | 10 |
| Target Price | $21.89 | ★ $48.20 |
| AVG Volume (30 Days) | ★ 2.3M | 440.6K |
| Earning Date | 11-04-2025 | 11-12-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 1.05 | N/A |
| Revenue | ★ $1,431,099,000.00 | N/A |
| Revenue This Year | $58.80 | N/A |
| Revenue Next Year | $45.35 | N/A |
| P/E Ratio | $21.40 | ★ N/A |
| Revenue Growth | ★ 30.30 | N/A |
| 52 Week Low | $6.79 | $5.49 |
| 52 Week High | $25.98 | $32.28 |
Technical Indicators
Market Signals| Indicator | SSRM | ORKA |
|---|---|---|
| Relative Strength Index (RSI) | 59.24 | 60.77 |
| Support Level | $21.61 | $27.84 |
| Resistance Level | $23.15 | $31.35 |
| Average True Range (ATR) | 1.02 | 1.96 |
| MACD | 0.14 | -0.21 |
| Stochastic Oscillator | 81.94 | 89.55 |
Price Performance
Historical ComparisonAbout SSRM SSR Mining Inc.
SSR Mining Inc is a minerals company focused on mining precious metals in the Americas. More than half of Silver Standard's revenue is attributable to the production of gold, with a key portion derived from silver production. The company owns and operates the Marigold mine in Nevada, United States; the Seabee Gold Operation in Saskatchewan, Canada; and the Puna mine in Argentina. The majority of gold production is derived from the Marigold mine, and Silver Standard's silver production is principally derived from the Puna mine.
About ORKA Oruka Therapeutics Inc.
Oruka Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing novel monoclonal antibody therapeutics for psoriasis (PsO) and other inflammatory and immunology (I&I) indications. Its lead program, ORKA-001, is designed to target the p19 subunit of interleukin-23 (IL-23p19) for the treatment of PsO. The company's co-lead program, ORKA-002, is designed to target interleukin-17A and interleukin-17F (IL-17A/F) for the treatment of PsO, psoriatic arthritis (PsA), and other conditions. These programs each bind their respective targets at high affinity and incorporate half-life extension technology to increase exposure and decreasing dosing frequency.